The United States Patent and Trademark Office (USPTO) has granted patent US12582722B2 to Nurix Therapeutics, Inc. This patent covers bifunctional compounds that degrade BTK via the ubiquitin proteolytic pathway, along with related pharmaceutical compositions and methods of use for treating various diseases. The patent was filed on February 4, 2020, and granted on March 24, 2026, with 21 claims.

This grant represents a new intellectual property asset for Nurix Therapeutics, Inc. in the field of targeted protein degradation. While this is a patent grant and not a regulatory rule, it signifies a new therapeutic approach that may eventually lead to new drug development. Compliance officers in the pharmaceutical sector should be aware of this patent as it pertains to novel drug candidates and potential future market exclusivity for treatments involving BTK degradation.